News & Events

John Quisel, JD, PhD Joins Disc Medicine as President and Chief Executive Officer

Co-founder and Interim CEO Brian MacDonald to Serve as Senior Advisor and Director Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced

More News

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and...

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs WATERTOWN,...

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic...